ClinicalTrials.gg
CompletedNCT03250624Updated May 1, 2023Results posted

Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis

A Phase 2 interventional study of CD5024 0.3% cream and Placebo in Atopic Dermatitis, sponsored by Galderma R&D. Completed at 5 sites in Canada. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-05-01.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Other

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Nov 2016, registered Aug 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Dermatitis, Atopic by Galderma Group AG — 3 open to participants now, 3 under way, 1 of them phase 3. Dermatitis, Atopic · Galderma Group AG.

Enrollment
12th of 16
63 · median 115
Started
2016
the only one that year
Phase 2
8 of 17
1 open now
Registered
5th of 17
by date

Among the 17 studies in Dermatitis, Atopic by Galderma Group AG, this one is the 12th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2016, is one of 8 in phase 2, and was the 5th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 17 studies in Dermatitis, Atopic by Galderma Group AG are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Dermatitis, Atopic by Galderma Group AG, or all of them as a file.
02

Study summary

Exploratory, multi-centric, randomized, vehicle-controlled, investigator-blind, parallel group study, involved participants with chronic lesions of Atopic Dermatitis (AD) to evaluate the local and systemic safety of CD5024 0.3% cream over a 6-week treatment period compared to its vehicle.

Read the detailed description

Study application was performed once daily, 7 days a week for 6 weeks.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant was a male or female aged 18 to 60 years old inclusive at Screening.
  2. The participant presented with a total body surface area (tBSA) less than or equal to (>=) 2 square meter (m\^2) at Screening.
  3. The participant had atopic dermatitis for at least 6 months prior to Day 1. The clinical diagnosis of atopic dermatitis must be confirmed with the criteria of Hanifin and Rajka at the screening visit.
  4. Atopic dermatitis must be stable for at least one month before the screening visit (according to participant).
  5. The participant had a Body Surface Area (BSA) affected by AD ranging from 1% inclusive to 10% inclusive at Day 1, excluding scalp and genitals.
  6. The participant had an overall Investigator's Global Assessment (IGA) score of 3 (moderate) at Day 1;

Exclusion criteria

Exclusion Criteria:

  1. The participant was a pregnant female, is breastfeeding or intends to conceive a child during the study,
  2. The participant had any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with the interpretation of the clinical trial results (e.g. extensive scaring or pigmented lesion in a treated area), and/or put the participant at significant risk according to Investigator's judgment if he/she participates in the clinical trial (e.g. active cancer, AIDS, insulin-dependent diabetes...) at Screening or Day 1.
  3. The participant presented with an acute flare of AD at Day 1.
  4. The participant had active cutaneous bacterial or viral infection in any treated area at baseline (e.g. clinically infected AD) at Screening or Day 1.
  5. The participant had a history of confounding skin condition (e.g. psoriasis, erythroderma) or a history of Netherton syndrome at Screening.
  6. The participant had a past history of serious persistent neurological disorders such as seizures, multiple sclerosis, or neurological signs or symptoms at Screening.
05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    CD5024 0.3% cream

    Drug: CD5024 0.3% cream

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Participants applied CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 milligrams per centimeter square (mg/cm\^2) once daily for 6 weeks.

    Also known as: Ivermectin

  • DrugPlacebo

    Participants applied placebo matched to CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 mg/cm\^2 once daily for 6 weeks.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Eczema Area and Severity Index (EASI) Score at Day 43

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum), with the higher scores indicated the worse severity of AD. All missing values were imputed by Last Observation Carried Forward (LOCF).

    Time frame: Baseline, Day 43

Secondary outcomes

  1. Percent Change From Baseline in EASI at Each Visit

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicated the worse severity of AD. All missing values were imputed by LOCF.

    Time frame: Baseline, Days 8,15, 22, 29, 36 and 43

  2. Percentage of Participants Who Achieved an Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)

    IGA scale consisted of 5 grades (0-4) among which 0 = Clear (Minor, residual discoloration, no erythema or induration/papulation, no oozing/crusting), 1 = Almost clear (Trace, faint pink erythema with almost no induration/papulation and no oozing/crusting), 2 = Mild (Faint pink erythema with mild induration/papulation and no oozing/crusting), 3 = Moderate (Pink-red erythema with moderate induration/papulation and there may be some oozing/crusting.), 4 = Severe (Deep/bright red erythema with severe induration/papulation with oozing/crusting). Success rate was defined as percentage of participants who achieved an IGA score of 1 (almost clear) or 0 (Clear) at specified visits. All missing values were imputed by LOCF.

    Time frame: Days 8, 15, 22, 29, 36 and 43

  3. Percent Change From Baseline in Total Sum Score (TSS) at Each Visit

    The TSS was the sum of individual clinical severity scores for 5 signs of AD (erythema, induration/papulation, oozing/crusting, excoriation and lichenification). The severity of each sign was evaluated by using a 4-graded scale (0: none; 1: mild; 2: moderate; 3: severe). The total score ranges from 0 to 15, where higher score indicated worse severity of AD. All missing values were imputed by LOCF.

    Time frame: Baseline, Days 8, 15, 22, 29, 36 and 43

  4. Percent Change From Baseline in Modified Objective Scoring Atopic Dermatitis (SCORAD) at Each Visit

    SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with visual analog scale (VAS) where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. Higher scores indicated worse outcome. All missing values were imputed by LOCF.

    Time frame: Baseline, Days 8, 15, 22, 29, 36 and 43

  5. Change From Baseline in Pruritus Numerical Rating Scale (NRS) at Each Visit

    Pruritus NRS was a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 = 'no itch' and 10 = 'worst itch imaginable', where higher score indicated very severe itch. All missing values were imputed by LOCF.

    Time frame: Baseline, Weeks 1, 2, 3, 4, 5 and 6

  6. Change From Baseline in Pruritus Verbal Rating Scale (VRS) Score at Day 43

    Participants were asked for a response that best described their pruritus intensity in last 24 hours, to rate their itch using a list of adjectives describing different levels of symptom intensity rated on a scale of 0 to 3 that is (i.e.) 0 = No itch, 1 = low, 2 = Moderate and 3 = Severe, where higher score indicated very severe itch. All missing values were imputed by LOCF.

    Time frame: Baseline, Day 43

07

Results

Posted May 1, 2023

Participant flow

The study was conducted at 5 centers in Canada between 01 November 2016 and 26 June 2017.

Participant flow — Overall Study
MilestoneCD5024 0.3% CreamPlacebo
Started3231
Completed3024
Not completed27
Withdrew: Lack of efficacy14
Withdrew: Adverse event01
Withdrew: Other12

Outcome measures

PrimaryChange From Baseline in Eczema Area and Severity Index (EASI) Score at Day 43

The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum), with the higher scores indicated the worse severity of AD. All missing values were imputed by Last Observation Carried Forward (LOCF).

Time frame:
Baseline, Day 43
Reported as:
Least squares mean · score on a scale
Change From Baseline in Eczema Area and Severity Index (EASI) Score at Day 43
score on a scaleCD5024 0.3% CreamPlacebo
Change From Baseline in Eczema Area and Severity Index (EASI) Score at Day 43-2.64 ± 0.41-2.36 ± 0.44
Statistical analysis
  • CD5024 0.3% Cream vs Placebo · ANCOVA · p = 0.632 · Least square (ls) mean difference: -0.28 · 95% CI -1.46 to 0.89
SecondaryPercent Change From Baseline in EASI at Each Visit

The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, induration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores indicated the worse severity of AD. All missing values were imputed by LOCF.

Time frame:
Baseline, Days 8,15, 22, 29, 36 and 43
Reported as:
Mean · percent change
Percent Change From Baseline in EASI at Each Visit
percent changeCD5024 0.3% CreamPlacebo
Day 8-8.7 ± 19.1-5.5 ± 39.6
Day 15-21.0 ± 37.5-10.7 ± 43.7
Day 22-29.1 ± 40.7-26.7 ± 35.8
Day 29-34.5 ± 59.9-21.0 ± 41.7
Day 36-43.1 ± 35.3-28.8 ± 44.7
Day 43-46.4 ± 38.8-24.6 ± 62.7
SecondaryPercentage of Participants Who Achieved an Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)

IGA scale consisted of 5 grades (0-4) among which 0 = Clear (Minor, residual discoloration, no erythema or induration/papulation, no oozing/crusting), 1 = Almost clear (Trace, faint pink erythema with almost no induration/papulation and no oozing/crusting), 2 = Mild (Faint pink erythema with mild induration/papulation and no oozing/crusting), 3 = Moderate (Pink-red erythema with moderate induration/papulation and there may be some oozing/crusting.), 4 = Severe (Deep/bright red erythema with severe induration/papulation with oozing/crusting). Success rate was defined as percentage of participants who achieved an IGA score of 1 (almost clear) or 0 (Clear) at specified visits. All missing values were imputed by LOCF.

Time frame:
Days 8, 15, 22, 29, 36 and 43
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Investigator Global Assessment (IGA) Score of 1 (Almost Clear) or 0 (Clear)
percentage of participantsCD5024 0.3% CreamPlacebo
Day 803.23
Day 153.136.45
Day 229.389.68
Day 2915.66.45
Day 3621.916.1
Day 4337.59.68
SecondaryPercent Change From Baseline in Total Sum Score (TSS) at Each Visit

The TSS was the sum of individual clinical severity scores for 5 signs of AD (erythema, induration/papulation, oozing/crusting, excoriation and lichenification). The severity of each sign was evaluated by using a 4-graded scale (0: none; 1: mild; 2: moderate; 3: severe). The total score ranges from 0 to 15, where higher score indicated worse severity of AD. All missing values were imputed by LOCF.

Time frame:
Baseline, Days 8, 15, 22, 29, 36 and 43
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Sum Score (TSS) at Each Visit
percent changeCD5024 0.3% CreamPlacebo
Day 8-15.35 ± 4.51-17.30 ± 4.75
Day 15-27.94 ± 5.76-20.82 ± 6.07
Day 22-29.38 ± 6.23-33.57 ± 6.57
Day 29-37.23 ± 6.64-34.44 ± 6.99
Day 36-45.01 ± 6.7542.24 ± 7.11
Day 43-47.63 ± 7.30-45.00 ± 7.69
SecondaryPercent Change From Baseline in Modified Objective Scoring Atopic Dermatitis (SCORAD) at Each Visit

SCORAD index uses the rule of nines to assess disease extent and evaluates 6 clinical characteristics to determine disease severity: (1) erythema, (2) edema/papulation, (3) oozing/crusts, (4) excoriation, (5) lichenification, and (6) dryness on a scale of 0 to 3 (0=absence, 1=mild, 2=moderate, 3=severe). The SCORAD index also assesses subjective symptoms of pruritus and sleep loss with visual analog scale (VAS) where 0 is no itching or no trouble sleeping and 10 is unbearable itching or a lot of trouble sleeping. These 3 aspects: extent of disease (A: 0-1-2), disease severity (B: 0-18), \& subjective symptoms (C: 0-20) combine using A/5 + 7\*B/2+ C to give a maximum possible score of 103, where 0 = no disease and 103 = severe disease. Higher scores indicated worse outcome. All missing values were imputed by LOCF.

Time frame:
Baseline, Days 8, 15, 22, 29, 36 and 43
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Modified Objective Scoring Atopic Dermatitis (SCORAD) at Each Visit
percent changeCD5024 0.3% CreamPlacebo
Day 8-16.28 ± 4.29-16.00 ± 4.52
Day 15-30.76 ± 5.51-20.49 ± 5.81
Day 22-32.02 ± 5.84-30.73 ± 6.16
Day 29-39.14 ± 6.51-31.81 ± 6.86
Day 36-46.38 ± 6.67-40.10 ± 7.03
Day 43-48.92 ± 7.26-41.48 ± 7.65
SecondaryChange From Baseline in Pruritus Numerical Rating Scale (NRS) at Each Visit

Pruritus NRS was a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 = 'no itch' and 10 = 'worst itch imaginable', where higher score indicated very severe itch. All missing values were imputed by LOCF.

Time frame:
Baseline, Weeks 1, 2, 3, 4, 5 and 6
Reported as:
Mean · score on a scale
Change From Baseline in Pruritus Numerical Rating Scale (NRS) at Each Visit
score on a scaleCD5024 0.3% CreamPlacebo
Week 1-0.2 ± 1.1-0.2 ± 1.4
Week 2-0.6 ± 1.9-0.3 ± 1.7
Week 3-0.7 ± 2.1-0.4 ± 1.9
Week 4-1.0 ± 2.3-0.3 ± 2.1
Week 5-1.0 ± 2.2-0.5 ± 2.0
Week 6-1.3 ± 2.4-0.6 ± 2.1
SecondaryChange From Baseline in Pruritus Verbal Rating Scale (VRS) Score at Day 43

Participants were asked for a response that best described their pruritus intensity in last 24 hours, to rate their itch using a list of adjectives describing different levels of symptom intensity rated on a scale of 0 to 3 that is (i.e.) 0 = No itch, 1 = low, 2 = Moderate and 3 = Severe, where higher score indicated very severe itch. All missing values were imputed by LOCF.

Time frame:
Baseline, Day 43
Reported as:
Mean · score on a scale
Change From Baseline in Pruritus Verbal Rating Scale (VRS) Score at Day 43
score on a scaleCD5024 0.3% CreamPlacebo
Change From Baseline in Pruritus Verbal Rating Scale (VRS) Score at Day 43-.31 ± 0.79-.13 ± 0.74

Adverse events

Collected over Up to Week 9. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD5024 0.3% Cream0/32 (0%)0/32 (0%)16/32 (50%)
Placebo0/31 (0%)0/31 (0%)21/31 (67.7%)
Most frequent other events
Showing 10 of 43
Most frequent other events
EventCD5024 0.3% CreamPlacebo
NasopharyngitisInfections and infestations6/3210/31
Abdominal painGastrointestinal disorders0/322/31
MyalgiaMusculoskeletal and connective tissue disorders0/322/31
Dermatitis atopicSkin and subcutaneous tissue disorders2/322/31
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/322/31
Upper respiratory tract infectionInfections and infestations2/321/31
HeadacheNervous system disorders2/321/31
GastroenteritisInfections and infestations1/321/31
Urinary tract infectionInfections and infestations0/321/31
Tinea crurisInfections and infestations0/321/31

Baseline characteristics

The Intent-to-treat (ITT) efficacy analysis set was defined as any participants who are randomized.

Age, Continuous
Age, Continuous(years)CD5024 0.3% CreamPlaceboTotal
Mean27.2 ± 9.1930.0 ± 10.7728.6 ± 9.98
Sex: Female, Male
Sex: Female, Male(Participants)CD5024 0.3% CreamPlaceboTotal
Female212647
Male11516
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CD5024 0.3% CreamPlaceboTotal
American Indian or Alaska Native000
Asian538
Native Hawaiian or Other Pacific Islander000
Black or African American156
White252348
More than one race000
Unknown or Not Reported101
Eczema Area and Severity Index (EASI) Score
Eczema Area and Severity Index (EASI) Score(score on a scale)CD5024 0.3% CreamPlaceboTotal
Mean5.341 ± 2.4325.371 ± 2.6525.356 ± 2.542
08

Study locations

5 sites
  • Galderma Investigational Site (#8581)
    Mississauga, Ontario L5H 1G9, Canada
  • Galderma Investigational Site (# 8338)
    Richmond Hill, Ontario L4B 1A5, Canada
  • Galderma Investigational Site (#8587)
    Richmond Hill, Ontario L4C 9M7, Canada
  • Galderma Investigational Site (# 8060)
    Windsor, Ontario N8W 5L7, Canada
  • Galderma Investigational Site (#8089)
    Montreal, Quebec H2K 4L5, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Jun 2017, 7 months.

Results were first posted in May 2023, 5 years 10 months after primary completion.

Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 7 months is below that.

Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2017
First posted
Aug 15, 2017
StartActual
Nov 1, 2016
Primary completionActual
Jun 26, 2017
CompletionActual
Jun 26, 2017
Results first posted
May 1, 2023
Last update
May 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03250624
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Aug 15, 2017
Start date
Nov 1, 2016
Primary completion
Jun 26, 2017
Completion
Jun 26, 2017
Results posted
May 1, 2023
Last update
May 1, 2023

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion